MED

Mission Produce Inc. AVO posted third-quarter fiscal 2026 results, wherein the top and bottom lines surpassed the Zacks Consensus Estimate. Meanwhile, earnings declined while revenues increased year over year.The company reported adjusted earnings of 16 cents per share compared with 24 cents in the year-ago quarter and surpassed the consensus estimate of 10 cents. The 60% beat came as results benefited from stronger-than-expected International Farming performance and encouraging contributions from Calavo. Mission Produce, Inc. price-consensus-eps-surprise-chart | Mission Produce, Inc. Quote Revenues of $450 million rose 25.8% year over year and topped the $368 million consensus estimate by 22.3%. Avocado volume increased 37.7% to 252.7 million pounds, reflecting the Calavo acquisition and higher legacy Mission Produce volume.Average avocado sales price declined 9.2% year over year to $1.58 per pound as elevated industry supply pressured pricing. Management said U.S. retail avocado volume grew about 9% year over year even as the average retail price increased about 15% sequentially.U.S. avocado consumption remained above 10 pounds per capita year to date, up 12% from last year, while household penetration increased about 50 basis points. Legacy Mission Produce also increased its estimated U.S. retail market share by about 60 basis points year to date.Gross profit was $44.7 million compared with $45.1 million a year ago. Gross margin fell 270 basis points to 9.9%, as lower International Farming pricing offset benefits from Calavo in Marketing & Distribution.SG&A, excluding transaction advisory and integration costs, increased to $31.6 million from $24 million, mainly due to Calavo's cost structure. Transaction advisory and integration costs were $12.6 million, while acquired inventory step-up amortization totaled $5.2 million.Adjusted EBITDA was $32.4 million versus $32.6 million last year and exceeded the high end of Mission Produce's prior $28 million to $32 million fiscal third-quarter guidance range. The outperformance reflected stronger-than-anticipated International Farming results and solid Calavo performance.Avocado operating metrics: 191.5 million pounds sold (up 15% y/y) at an average sales price of $1.29 per pound (down 35.5% y/y from $2). Marketing & Distribution sales increased 20.4% year over year to $414.3 million, helped by higher avocado volume. Segment adjusted EBITDA rose 23.5% to $24.7 million, primarily reflecting higher gross margin from Calavo's post-acquisition contribution.Prepared Foods, now reported separately following the acquisition, generated $15.5 million in sales and $0.2 million in adjusted EBITDA for the post-acquisition period. Management noted that the results cover only part of the quarter and are not representative of a full-quarter run rate.International Farming sales declined 6.5% year over year to $45.8 million, while segment adjusted EBITDA fell 37.2% to $7.6 million. Lower average avocado sales prices weighed on the comparison, though stronger-than-expected sales returns drove results above management's expectations.Mission Produce expects 120 million to 130 million pounds of exportable avocado production from its owned Peru farms this season, up from 105 million pounds last year. About 53 million pounds had been sold through the end of the fiscal third quarter, leaving a greater concentration of sales for the fiscal fourth quarter.Blueberries segment sales rose 20.0% to $5.4 million, while adjusted EBITDA was a loss of $0.1 million compared with an income of $0.5 million a year ago. Most blueberry sales and profitability are concentrated in the fourth and first quarters. Cash and cash equivalents were $47.1 million as of July 31, 2026, down from $64.8 million as of Oct. 31, 2025. Total long-term debt, including the current portion and net debt issuance costs, was about $400.3 million, while quarterly interest expense increased to $5.1 million from $2.4 million.Net cash used in operating activities was $25.9 million for the first nine months, compared with $21.4 million of cash provided a year earlier. Capital expenditures totaled $32 million versus $39.8 million last year, and Mission Produce repurchased $9.4 million of common stock during the period. Mission Produce reaffirmed second-half fiscal 2026 adjusted EBITDA guidance of $84 million to $88 million. Management expects fiscal fourth-quarter adjusted EBITDA of $52 million to $55 million, supported by later Peru avocado sales, higher blueberry activity, a full quarter of Calavo and improved avocado margin dynamics.For the fiscal fourth quarter, industry avocado volumes are expected to rise about 10% year over year, while pricing is projected to decline about 10% from the prior-year average of $1.39 per pound. Mission Produce also raised its annualized Calavo synergy target to more than $30 million from at least $25 million, with savings expected to begin contributing in the fiscal fourth quarter and build through fiscal 2027.Shares of this Zacks Rank #3 (Hold) company have gained 14.5% in the last three months compared with the industry’s growth of 10.4%. Image Source: Zacks Investment Research The Chef’s Warehouse, Inc. CHEF distributes specialty food and center-of-the-plate products in the United States, the Middle East and Canada. CHEF currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for CHEF’s current fiscal-year sales and earnings indicates growth of 10.6% and 33.7%, respectively, from the year-ago reported figures. CHEF delivered a trailing four-quarter earnings surprise of 30.4%, on average.Medifast, Inc. MED, which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank #2 (Buy). MED missed the average earnings surprise by a sharp margin in the trailing four quarters.The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 27.3% from the year-ago number.United Natural Foods UNFI, which is the leading distributor of natural, organic and specialty food and non-food products, currently has a Zacks Rank of 2.The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Mission Produce, Inc. (AVO) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF) : Free Stock Analysis Report MEDIFAST INC (MED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

It has been about a month since the last earnings report for BellRing Brands (BRBR). Shares have lost about 15% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is BellRing Brands due for a breakout? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent catalysts for BellRing Brands Inc. before we dive into how investors and analysts have reacted as of late. BellRing Brands reported third-quarter fiscal 2026 results wherein earnings declined year over year and missed the Zacks Consensus Estimate. However, revenues increased year over year and came ahead of the consensus mark.The company posted adjusted earnings of 30 cents per share for the third quarter of fiscal 2026, down 45.5% from 55 cents in the prior-year quarter. The figure missed the Zacks Consensus Estimate of 37 cents.Net sales increased 4.2% to $570.4 million from $547.5 million in the year-ago quarter and exceeded the Zacks Consensus Estimate of $562 million. Higher Premier Protein shake volume, driven by distribution gains and robust Dymatize sales growth, supported revenues, while significant input cost inflation, including tariffs, higher freight expenses and inventory-related charges, weighed on profitability. Premier Protein net sales increased 0.7% year over year. Volume rose 1.5%, while price/mix declined 0.8%, reflecting incremental promotional investments. Premier Protein ready-to-drink (RTD) shake sales increased 1.2% from the prior-year quarter. Volume grew 3.1%, whereas price/mix declined 1.9%. Premier Protein RTD consumption increased 6% year over year. Premier Protein RTD consumption rose 50.9% in e-commerce, 26.1% in food and 10.1% in mass channels, while club consumption declined 7.6%. Dymatize net sales climbed 26.7% year over year. Volume increased 6%, while price/mix improved 20.7%, reflecting pricing actions implemented to offset inflationary costs and distribution gains in international markets. Dymatize consumption increased 2.7% from the year-ago period. By channel, e-commerce sales increased 18%, while mass sales declined 11.9%, specialty and all other sales fell 3.9%, food sales decreased 12.2%, and club sales dropped 53%. Adjusted gross profit declined 17.9% to $157.9 million from $192.4 million in the prior-year quarter. Adjusted gross margin contracted 740 basis points to 27.7% from 35.1%. The decline reflected significant input cost inflation, including tariffs, higher freight expenses and a $10 million charge related to excess shake bottle inventory. The inventory charge reduced adjusted gross margin by 180 basis points. Selling, general and administrative expenses declined 35.2% to $93.7 million from $144.5 million, including reorganization charges of $5.4 million. As a percentage of sales, SG&A improved to 16.4% from 26.4%.Adjusted EBITDA decreased 34.9% to $78.3 million from $120.3 million a year earlier. Management said that the excess shake bottle inventory charge and higher-than-expected freight costs were the primary reasons adjusted EBITDA came in below internal expectations. Operating profit increased 46% to $65.4 million from $44.8 million, as lower reported SG&A expenses more than offset the decline in gross profit. Cash and cash equivalents totaled $50.4 million as of June 30, 2026, compared with $71.8 million as of Sept. 30, 2025. Inventories increased to $480.6 million from $330.4 million, while long-term debt rose to $1,135.3 million from $1,084.3 million over the same period. Operating cash flow for the first nine months of fiscal 2026 declined to $65 million from $91.5 million in the comparable prior-year period. During the first nine months of fiscal 2026, BellRing repurchased 4.9 million shares for $133.1 million. As of June 30, 2026, the company had $506.9 million remaining under its existing share repurchase authorization. For the fourth quarter of fiscal 2026, BellRing expects net sales to be flat at the midpoint of its outlook. Premier is anticipated to post low-single-digit sales growth, including an approximate 100-basis-point headwind from powders. The company also projects double-digit growth in RTD shake volumes, with the benefit expected to be largely offset by weaker price/mix stemming from elevated promotional activity across the club, mass and e-commerce channels.BellRing forecasts an adjusted EBITDA margin of approximately 10% for the fourth quarter. The margin outlook reflects the impact of seasonal promotional spending, continued commodity and freight cost inflation ahead of planned pricing actions, as well as initiatives to reduce excess shake bottle inventory, which are expected to lower the quarterly adjusted EBITDA margin by roughly 100 basis points.For fiscal 2026, BellRing increased its net sales outlook to $2.335-$2.375 billion, representing 1-3% year-over-year growth compared with its earlier expectation of flat to 2% growth. Since the earnings release, investors have witnessed a downward trend in estimates revision. The consensus estimate has shifted -41.34% due to these changes. Currently, BellRing Brands has a nice Growth Score of B, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of A on the value side, putting it in the top 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, BellRing Brands has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months. BellRing Brands is part of the Zacks Food - Miscellaneous industry. Over the past month, Medifast (MED), a stock from the same industry, has gained 3.2%. The company reported its results for the quarter ended June 2026 more than a month ago. Medifast reported revenues of $76.38 million in the last reported quarter, representing a year-over-year change of -27.6%. EPS of -$0.28 for the same period compares with $0.04 a year ago. Medifast is expected to post a loss of $0.40 per share for the current quarter, representing a year-over-year change of -90.5%. Over the last 30 days, the Zacks Consensus Estimate has changed +33.3%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #2 (Buy) for Medifast. Also, the stock has a VGM Score of D. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BellRing Brands Inc. (BRBR) : Free Stock Analysis Report MEDIFAST INC (MED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

A month has gone by since the last earnings report for Medifast (MED). Shares have lost about 7.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Medifast due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Medifast reported second-quarter 2026 results, wherein both the top and bottom lines surpassed the Zacks Consensus Estimate. However, both metrics declined year over year. The company posted a loss per share of 28 cents, narrower than the Zacks Consensus Estimate of a loss of 67 cents per share. The company posted earnings of 22 cents per share in the prior-year period. Revenues declined 27.6% year over year to $76.4 million from $105.6 million, slightly exceeding the Zacks Consensus Estimate of $76 million. Higher revenues generated by each active earning coach reflected continued improvements in coach productivity despite a smaller coach network. Medifast ended the quarter with approximately 11,700 active earning coaches, down 48.7% from 22,800 a year earlier. Management said that the decline in coaches remained the primary factor behind the year-over-year revenue decrease. The company noted that slower client acquisition continues to reflect broader industry pressures, including the rapid adoption of GLP-1 weight-loss medications. Average revenue per active earning coach increased 41% year over year to $6,529 from $4,630, marking the third consecutive quarter of productivity improvement. Management continues to view stronger coach productivity as an early indicator of future business improvement, noting that historically it has been followed by higher client acquisition, coach growth and revenue expansion. Gross profit fell 30.3% year over year to $53.4 million from $76.6 million, due to lower sales volumes. Gross margin contracted 270 basis points to 69.9% from 72.6%, primarily due to reduced leverage on fixed costs. Selling, general and administrative expenses were $57.7 million, declining 25.7% year over year from $77.7 million. The decrease reflected $12.6 million of lower coach compensation, $2.3 million of reduced employee salary and benefit expenses and $2 million of lower company-led marketing costs. SG&A expenses represented 75.6% of revenues, up 200 basis points from 73.6% a year ago. The increase primarily reflected fixed-cost deleverage and expenses associated with the Trilivy Reset product launch, partly offset by lower marketing spending. The operating loss widened to $4.3 million from $1.1 million in the year-ago quarter. Medifast ended June 2026 with $169.8 million in cash, cash equivalents and investment securities compared with $167.3 million at Dec. 31, 2025. The company remained debt-free. For the third quarter of fiscal 2026, Medifast expects revenues of $60-$80 million and a loss of 15-65 cents per share, excluding one-time costs related to the Catalyst cost-savings program. Management expects the active earning coach count to continue declining in the near term but anticipates further improvement in coach productivity on both a year-over-year and sequential basis during the third quarter. For fiscal 2026, Medifast reaffirmed its revenue outlook of $270-$300 million and now expects a loss in the range of 25 cents to $1.75 per share compared with the previous guidance of a loss of $1.55-$2.75 per share. The company continues to expect progress toward returning to profitability beginning in the fourth quarter of 2026 following the launch of its new product line, with further earnings improvement targeted through 2027 and beyond. Management also expects working capital to exceed $145 million by year-end. The company noted that its Catalyst program is expected to generate savings through facility rationalization, AI-related efficiencies and other operational initiatives. It turns out, fresh estimates have trended upward during the past month. The consensus estimate has shifted 33.33% due to these changes. At this time, Medifast has a average Growth Score of C, however its Momentum Score is doing a bit better with a B. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been trending upward for the stock, and the magnitude of this revision looks promising. It comes with little surprise Medifast has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months. Medifast is part of the Zacks Food - Miscellaneous industry. Over the past month, Chefs' Warehouse (CHEF), a stock from the same industry, has gained 5%. The company reported its results for the quarter ended June 2026 more than a month ago. Chefs' Warehouse reported revenues of $1.17 billion in the last reported quarter, representing a year-over-year change of +12.9%. EPS of $0.78 for the same period compares with $0.52 a year ago. Chefs' Warehouse is expected to post earnings of $0.61 per share for the current quarter, representing a year-over-year change of +22%. Over the last 30 days, the Zacks Consensus Estimate has changed +11.7%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #1 (Strong Buy) for Chefs' Warehouse. Also, the stock has a VGM Score of C. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report MEDIFAST INC (MED) : Free Stock Analysis Report The Chefs' Warehouse, Inc. (CHEF) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Medifast’s second quarter was marked by stabilization in key business metrics despite continued pressure from declining coach numbers and shifting industry trends. The company’s revenue and earnings surpassed Wall Street expectations, contributing to a strong positive market reaction. Management credited improved coach productivity—up for the third consecutive quarter—and the early impact of its new consumer brand, Trilivy, as key drivers of sequential stabilization. CEO Nick Johnson highlighted, “Coach productivity was positive for the third straight quarter, with the highest revenue per active earning coach since 2022.” Is now the time to buy MED? Find out in our full research report (it’s free). Revenue: $76.38 million vs analyst estimates of $72.7 million (27.6% year-on-year decline, 5.1% beat) EPS (GAAP): -$0.28 vs analyst estimates of -$0.65 (56.9% beat) The company reconfirmed its revenue guidance for the full year of $285 million at the midpoint EPS (GAAP) guidance for the full year is -$1 at the midpoint, beating analyst estimates by 39% Operating Margin: -5.7%, down from -1% in the same quarter last year Market Capitalization: $130.5 million While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Jim Salera (Stephens Inc.) asked for details on the Catalyst program’s implementation costs and expected savings. CFO Jim Maloney replied that while millions in annual savings are targeted, specifics will be disclosed in the next quarter as the company finalizes plans. Jim Salera (Stephens Inc.) questioned whether the path to profitability in Q4 2026 relies solely on Catalyst or if other factors contribute. Maloney emphasized both cost savings from Catalyst and top-line stabilization, reinforced by new product launches, as key levers. Jim Salera (Stephens Inc.) inquired about coach receptivity to the Trilivy rollout and any transition challenges. CEO Nick Johnson reported overwhelmingly positive feedback from the field, with no major issues observed during the shift from OPTAVIA. Jim Salera (Stephens Inc.) asked how new products and compensation changes might impact margins. Maloney explained that top-line stabilization and cost actions should improve margins, with further benefits as the business grows and fixed costs are leveraged. Jim Salera (Stephens Inc.) probed for clarity on future margin trajectory as coach productivity rises. Maloney reiterated that increasing productivity historically leads to coach and revenue growth, which should positively impact fixed cost leverage over time. Looking to the rest of the year, the StockStory team will be monitoring (1) the impact of the Trilivy brand and new product launches on client and coach retention, (2) the pace and effectiveness of cost savings under the Catalyst initiative, and (3) ongoing trends in coach productivity as a precursor to potential revenue growth. Execution on these milestones will be critical to assessing progress toward profitability. Medifast currently trades at $12.64, up from $9.74 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members). ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies. Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE. Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.

Image source: The Motley Fool. Monday, Aug. 3, 2026 at 8:00 a.m. ET Chief Executive Officer - Nicholas Johnson Chief Financial Officer - James Maloney Vice President, Investor Relations - Steven Zenker Operator: Greetings, and welcome to the Medifast Second Quarter 2026 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Steven Zenker, Vice President, Investor Relations. Thank you, sir. You may begin. Steven Zenker: Good afternoon, and welcome to Medifast's Second Quarter 2026 Earnings Conference Call. On the call with me today are Nick Johnson, Chief Executive Officer; and Jim Maloney, Chief Financial Officer. By now, everyone should have access to the earnings release for the second quarter ended June 30, 2026, that went out this afternoon at approximately 4:05 p.m. Eastern Time. If you have not received the release, it is available on the Investor Relations portion of Medifast's website at www.medifastinc.com. This call is being webcast and a replay will also be available on the company's website. Before we begin, we would like to remind everyone that today's prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. The words believe, expect, anticipate, and other similar expressions generally identify forward-looking statements. These statements do not guarantee future performance and therefore undue reliance should not be placed on them. Actual results could differ materially from those projected in any forward-looking statements. All of the forward-looking statements contained herein speak only as of the date of this call. Medifast assumes no obligation to update any forward-looking statements that may be made in today's release or call. Now I would like to turn the call over to Medifast's Chief Executive Officer, Nick Johnson. Nicholas Johnson: Thanks, Steve, and good afternoon, everyone. It's an honor to be addressing you today in my first earnings call as the CEO of Medifast, and I'm looking forward to conversations with investors over the months and years ahead. In our second quarter, we continued to see positive indicators in our business, maintaining a trend that began in late 2025. Most notably, revenue has stabilized sequentially over the recent quarters, aided by higher coach productivity, which grew for the third consecutive quarter. This is a key metric for us as positive trends historically have preceded revenue and profitability growth. Improved coach productivity is also reflected in the growing percentage of active earning coaches reaching Executive Director rank as our field embraces our strategic transition to metabolic health. We anticipate that these positive trends will continue through the remainder of the year, supported by the launch of our new consumer brand, Trilivy. Trilivy is the first step in our 3.0 strategy, which is the biggest shift for Medifast since we launched OPTAVIA in 2017. The strategy is defined by a 10-year roadmap that will allow us to expand our offer to coaches and clients in the context of a comprehensive metabolic health system, while also broadening our geographic and demographic footprints. We have made substantial progress this year, launching a new brand, a new scientific institute, an enhanced coach compensation structure, and a standardized training system for our coaches. Each is a significant step forward, and together they help form a foundation for us to win in the metabolic health category. The way we are running the 3.0 organization centers around four core defining characteristics, namely speed, simplicity, scale, and stewardship. We have to move quickly to take advantage of the opportunity that exists in metabolic health, while also returning the business to profitability. This speed imperative is reflected in the launch of a series of new initiatives that we will share more about on this call, but also in setting and maintaining a sustainable pace to our work and finding ways to do more with less. Simplicity is part of the narrative that underpins our business model and the ease with which we empower coaches to build their businesses. The less complexity our coaches face, the more they can focus on what actually grows their businesses. We have to eliminate what doesn't serve our coaches and clients and optimize the things that do. Scale matters because everything we are building is designed to compound. Each new coach and client fuels our flywheel, while stewardship underlines our commitment to building a business that is consistently profitable and that delivers for years to come. A key source of fuel for our flywheel is our new consumer brand, Trilivy, which succeeds OPTAVIA as our primary consumer brand. For years, the OPTAVIA brand was known primarily for one outcome, weight loss, which was just a single element of its effectiveness in helping people live a healthier lifestyle. Trilivy reflects the holistic health benefits our system is intended to deliver, a metabolic reset that helps the body work better over time, through three distinct phases: Reset, Refine, and Renew. Our science supports clients from end to end in a clear and compelling way that better aligns the brand with the daily realities of our coaches and clients, today and into the future. We believe the opportunity is large. More than 90% of U.S. adults and 1.5 billion adults worldwide are metabolically unhealthy. Our study of more than 1,000 adults found nearly 94% are concerned about at least one aspect of their metabolic health. 85% believe metabolic dysfunction can be reversed, and 84% see it as central to overall well-being, but 80% say they do not really understand what metabolic health means. So, there is high public concern, a belief that change is possible, but low understanding of how to do that. Our science-backed, coach-guided system closes that understanding gap. Attention on body composition, lean mass, and muscle preservation has never been higher, as GLP-1 adoption and awareness continues to grow. Our comprehensive metabolic health system offers holistic lifestyle change and behavioral modification through the coaching and structured nutrition that is central to all of our plans. We continue to engage the GLP-1 market and beyond, supporting people throughout their health journey, whether they're using medication, coming off it, or pursuing metabolic health through non-medication pathways. Our coach-led program builds on more than 45 years of clinical and scientific heritage and is built around metabolic synchronization, our proprietary science that reverses metabolic dysfunction. Our clinically proven plans activate targeted fat burn while preserving lean mass. Our most popular plan reduces visceral fat by 14% while retaining 98% of lean mass over 16 weeks. And in a clinical study, clients working with a coach lost up to 10x more weight and 17x more fat than those trying on their own. That is the structural advantage at the heart of our model, and it sets us apart in a crowded market. In July, we launched the Medifast Metabolic Health Institute with a mission to advance metabolic health through rigorous research and credible evidence-based education. Led by recognized experts, including a dedicated scientific advisory board, and backed by teams with more than 390 years of collective professional experience, the Institute organizes our work across research, product development, scientific communications, and education. It serves a clear commercial purpose: to strengthen the evidence base behind our programs, continue to substantiate an expanding set of health claims, and establish Medifast as a trusted authority in a field that most of the market is only beginning to understand. We expect that this is how we turn our scientific heritage into a durable, competitive advantage. We continue to build on our clinically proven science, utilizing our MetaVantage Technology platform with the upcoming launch of our new Reset Fuelings. Each Fueling, like those in our previous Fuelings line, is nutrient-dense and pre-portioned, with high-quality protein, fiber, probiotics, and more than two dozen vitamins and minerals. Added to the new product line are three key ingredients intended to make our products even more effective. This proprietary MetaVantage Technology Reset formula is designed to unlock key metabolic pathways to help support normal fat metabolism, healthy insulin function, and reduced waist circumference. The new Fuelings anchor our clinically proven Reset 5 and 1 Plan, which activates a targeted fat burn to improve body composition, reducing visceral fat while retaining lean mass. This is our first product line designed to fully utilize our MetaVantage Technology reset formula, and it strengthens our overall market differentiation. We ran a pilot this spring with certain employees, coaches, and clients, and the feedback was overwhelmingly positive. We look forward to putting these products into the hands of all clients and coaches later this month. In the field, engagement is high, and that's showing in the metrics. Although the number of coaches continues to decline, active earning coach productivity was positive for the third straight quarter, with year-over-year productivity up 41% and sequentially up 20% versus our first quarter. Revenue per active earning coach is now the highest it has been since the second quarter of 2022, and we expect the trend to continue through 2026. On August 1st, we launched an enhanced compensation plan that significantly sharpens our focus on developing and duplicating Executive Directors. As high-producing coaches, Executive Directors are the single greatest driver of sustainable growth for our business. The design of our new compensation plan was heavily informed by the success of our EDGE program, which confirmed our belief that focusing our field on building Executive Directors empowers stronger leadership development and healthier field performance. The momentum we are seeing today reflects those EDGE results, with the percentage of active earning coaches at the Executive Director rank or above continuing to climb, remaining over our 10% benchmark for a healthy, scalable field organization. This is a big area of focus for us as we move forward, and we believe our enhanced compensation plan builds on this proven foundation and will further accelerate growth over time. Our client referral program continues to exceed expectations, which is important as we launch the new product line and seek to capitalize on the enthusiasm and energy of the coaches as they lean into the new metabolic health narrative with clients. The renewed energy and excitement from the coach base was on display at our sold-out coach convention in July and was a clear indicator of the strength of coach engagement right now. We used the opportunity to focus coach attention on key initiatives, including Trilivy's new products, the simplified compensation plan, and our new coach-developed Trilivy Coach Hub training platform. Simplifying the fundamentals of our products and programs, but also the way we talk about them, is a critical component of our collective commitment to bringing the company back to profitability and improving the scalability of our business. The energy at the conference was remarkable, and it's encouraging to see a new generation of coaches engaging with the new brand and the enhanced approach to metabolic health as we seek to Reset, Refine, and Renew lives. Before I turn it over to Jim for a detailed look at the financials, I want to touch on a few key data points. We met expectations for the quarter on both revenue and earnings. Second quarter revenue was $76 million, in line with the guidance we provided in May. The results reflect higher coach productivity and improved client retention trends, and is consistent with a business whose operating indicators are starting to turn more positive. Our balance sheet remains a source of strength. We ended the quarter with more than $169 million in cash and investments and no debt. Our enterprise value today sits below the value of our cash and investments. The restructuring actions of the past two years reduced our cost base significantly, while preserving the capabilities we need to grow. During Q2, we launched our Catalyst program with the majority of the execution expected to take place in Q3. The Catalyst program is designed to drive additional cost savings through facility rationalization, AI-related efficiencies, and other means, all while being certain we do not negatively impact our ability to grow. By intensifying our focus on improving profitability, we believe we will be in a stronger financial position to execute our 10-year growth strategy successfully. Our near-term focus is straightforward. We aim to return to profitability by the fourth quarter of 2026. We are executing on both sides of the equation, enhancing initiatives to grow revenue and eliminating cost across the business, and we believe we are on track to deliver it. All of this comes back to my earlier comments about running this organization on the key tenets of speed, simplicity, scale, and stewardship. We are moving fast without overreaching, simplifying how our coaches build their businesses, and building a model designed to strengthen as the field grows. We have a clear long-term plan built around helping clients achieve optimal metabolic health. It is backed by breakthrough science and delivered through a coach-led model that we believe is a real structural advantage. We are already seeing progress in key areas of our business ahead of the impact of the new brand, products, and training. We have the science, the brand, the products, and the coaches to compete and win in metabolic health, and we have the financial strength to create a platform for growth. There is more to be done, but we have entered the second half of the year with a clear focus on fulfilling both our short- and long-term business objectives. With that, I'll hand over to Jim to run through the financials. James Maloney: Thank you, Nick. Good afternoon, everyone. Second quarter 2026 revenue was within our guidance range, and second quarter EPS exceeded our guidance range, supported by a third consecutive quarter of year-over-year coach productivity growth. Revenue for the second quarter was $76.4 million, a decrease of 27.6% versus the year earlier period, primarily due to a decrease in the number of active earning coaches. We ended the quarter with approximately 11,700 active earning coaches, a decrease of 48.7% from the second quarter of 2025. The company continues to see an impact from the rapid adoption of GLP-1 medication across the traditional weight loss category, which is contributing to this decline. In response, we continued our work on building a new coach leadership structure, which includes deprioritizing less productive coaches and developing a network of the most productive Executive Directors organizations. This work resulted in average revenue per active earning coach for the second quarter of $6,529, a year-over-year increase of 41.0%. We now have a clear trend of increasing coach productivity both year-over-year and sequentially. We continue to believe that increases in revenue per active earning coach are an early indicator for future coach growth, which we believe will in turn lead to revenue growth. Gross profit for Q2 2026 decreased 30.3% year-over-year to $53.4 million, driven by lower sales volumes. Gross profit margin for the current quarter was 69.9% compared to 72.6% for the second quarter of 2025, primarily driven by the loss of leverage on fixed costs. SG&A expense was down 25.7% year-over-year to $57.7 million, primarily due to a $12.6 million decrease in coach compensation on lower volume and fewer active earning coaches, a $2.3 million decrease in employee salary and benefit expenses, and a $2 million decrease in company-led marketing costs. SG&A as a percentage of revenue increased 200 basis points, primarily due to approximately 290 basis points associated to loss of leverage on fixed costs and 60 basis points associated with the launch of the company's new Trilivy reset product line, partially offset by a 190-basis-point reduction related to company-led marketing costs. As Nick mentioned earlier, we launched our Catalyst program during Q2, and we'll have more to share about these cost savings and streamlining initiatives as they ramp up in Q3. We continue to include in our guidance the belief that improvements to get back to profitability will start in Q4 2026, and the Catalyst program will be a large part of how we accomplish that objective. Loss from operations was $4.3 million in the second quarter of 2026, an increase in losses of $3.3 million versus the year earlier period, as the decline in gross profit was largely offset by lower SG&A. As a percentage of revenue, loss from operations was 5.7% in the second quarter, a 470 basis points change from 1.0% in the year-earlier comparable period. Other income decreased $2.6 million year-over-year to $1.3 million, primarily due to gains on our investment in LifeMD common stock in the year-earlier period. As a reminder, we sold our common stock investment in LifeMD during the second quarter of 2025. The income tax expense for the period was $0.1 million, an effective rate of negative 3.6%, as compared to $0.4 million for the second quarter of 2025, an effective rate of 13.7%. Due to the existence of a full valuation allowance against its deferred tax assets recorded as of December 31, 2025, the company calculated income tax expense for the current period based on actual results for the quarter. The decrease in the effective tax rate was primarily driven by the increased loss incurred in the June 30, 2026 period and the valuation allowance on the net deferred tax assets. Net loss in the second quarter of 2026 was $3.1 million, or $0.28 per diluted share, compared to a net income of $2.5 million, or $0.22 per share, in the year earlier period. With respect to our balance sheet, we ended the year with $169.8 million in cash, cash equivalents, and investments, and no debt as of June 30, 2026. Additionally, our working capital, defined as current assets less current liabilities, was $160.5 million as of December 31, 2025. Now I'll turn to guidance. We are expecting third quarter revenue to range from $60 million to $80 million and loss per share for the quarter to range from $0.15 to $0.65. This excludes any one-time costs associated with the execution of our Catalyst initiatives. While we expect to continue to see the active earning coach count to decline in the short term, we expect to see continued coach productivity growth during the quarter, up both year-over-year and sequentially. For the full year 2026, we expect revenue to range from $270 million to $300 million, and loss per share between $0.25 and $1.75. Also, we continue to include in our guidance the belief that improvements to get back to profitability will start in Q4 2026, following the launch of our new product line, and we will be targeting improvements in earnings to continue into 2027 and beyond. Finally, we believe that our working capital will be more than $145 million at December 31, 2026. With that, let me turn the call back to the operator for questions. Operator: [Operator Instructions] Our first question comes from Jim Salera with Stephens Inc. James Salera: We're going to start out with some questions around the Catalyst program. I think investors will be encouraged to hear visibility towards profitability in 4Q of '26. We'd love some more detail around, I guess, the initial implementation costs of the Catalyst program, the expected savings, and maybe kind of the cadence of when we should start to see the costs flow through the P&L versus the realization of the savings. James Maloney: Yes, so Jim, we were very intentional in our prepared remarks to say that there's going to be more to come on the Catalyst program and its savings. What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce. The focus of Catalyst is to take and simplify the business, but not take costs out that will impact top-line revenues. So, we're still continuing to do certain investments within the top line that we believe will help that. And we're continuing to focus on Executive Directors, but we're not able to give the exact quantifications at this point. We are going to be doing that in our Q3 earnings call. James Salera: Okay. If we think about the path to profitability or return to profitability in 4Q, is the Catalyst program the only lever there, or are there some other incremental contributors, whether it be top-line recovery, the new product launch, I don't know if there's any sort of margin change there, but anything that you could help give us kind of the building blocks for that 4Q. James Maloney: Yes, I mean, we kept our guidance on the top line the same versus last quarter. So, you're seeing that the last three quarters, so Q4 of 2025, was approximately $75 million in revenue. Q1 and Q2 was also approximately $75 million in revenue. And we're targeting anywhere in the range of the guidance range that we gave of $60 million to $80 this upcoming quarter. And when you do the math at the midpoint, say we get to $70 million in revenue in Q3 at the midpoint, we'll have to get close to that number again in Q4 to be at the midpoint of the range. So, that gives you a feel of the top line, and we didn't change the top line at all. And we're feeling more and more confident in that top line. The EPS range that we're providing has actually gotten better. So, when you look at the full year range of what we provided last quarter versus this quarter, even though we are excluding certain one-time charges, which we'll call out in our Q3 earnings call what those were, Q4, when you do the math, will actually, you'll see how it gets better. James Salera: Okay. Maybe one more for me. With the launch of the revamped product offering in Trilivy, can you just walk us through coach receptivity to that, how the transition of moving people over from the old OPTAVIA system to the new system is going? And any hiccups or bumps we should think about there? And then I guess once we're kind of fully switched over, maybe some of the incremental opportunities that provides versus the old platform? Nicholas Johnson: Thanks, Jim. I'll take the first part of the question, which is around the receptivity across the field. And then with respect to the specifics of the rollout, margin, anything of that nature, I'll turn it over to our Jim to go over those. Perspective, we saw a tremendous amount of positive reception to the change notably around our ability to develop a metabolic health platform, which goes beyond what we've traditionally been known for inside of the OPTAVIA brand as weight loss. So, number one, an expanded opportunity rooted in metabolic health. Two, we launched a series of initiatives in addition to the new brand. And what we're seeing so far with respect to the coach pre-launch of new Trilivy Fuelings has been very, very positive. We've seen a lot of activity in that space so far. So, from the sold-out event at our convention a few weeks ago to the uptake of the coach pre-launch, we're seeing that as a good signal of receptivity of the change. We've seen no major hiccups with respect to that change in the evolution of the brand. Instead, we've seen a lot of positivity from our field with respect to the renewed opportunity inside of metabolic health. We do have a plan to roll out those Fuelings across the next quarters. And so, I'll have Jim comment on what that's looking like in addition to any sort of improvement on the margin side. James Maloney: Yes, I mean, so overall, speaking to 2026, stabilization of our top line will help our margins and then with the impact of what we did in past quarters and moving into Catalyst, that should help with margins. So as we move from a loss in Q2, and we move into focusing on Q4, we do expect better overall margins to our business. And then think about 2027, so we are saying that we're focusing on profitability in 2027 also. And when you think about the last several quarters, what we've talked about, the majority of our margin loss has been due to the loss of leverage of the decline. And we -- as the business stabilizes into 2027 and beyond and starts to grow, that loss of leverage actually starts to become a positive. So, as we mentioned in our prepared remarks, this increase in productivity per coach in our past history that has led to coach growth, which then has led to revenue growth, so we are expecting that to reoccur. Obviously we're in a different world with GLP-1 medications, but there's nothing, at least at this point, telling us anything differently that we should expect at some point that coach growth will happen and we'll start picking up the leverage points of our fixed cost as the business grows in the out periods. Operator: We have reached the end of our question and answer session. I'd now like to turn the floor back over to Nick Johnson for closing comments. Nicholas Johnson: Thank you everyone for joining us today and for your continued interest in Medifast. As we move through the second half of 2026, our focus remains steadfast on executing our 3.0 strategy and driving the successful rollout of the Trilivy brand. We are energized by the positive momentum in coach productivity and engagement, and are confident that the foundational work we are doing today centering on speed, simplicity, scale, and stewardship is setting the stage for a return to profitability in the fourth quarter. We look forward to updating you on our progress during our next call. Have a great afternoon. Operator: This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation. Before you buy stock in Medifast, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Medifast wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $399,832!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,374,595!* That performance is why people listen. With a track record of beating the S&P 500 by 4x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 10, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Medifast (MED) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Dole plc DOLE reported second-quarter 2026 adjusted earnings per share of 46 cents, down 16.4% from 55 cents in the year-ago quarter and below the Zacks Consensus Estimate of 50 cents. Revenues increased 2.9% year over year to $2.5 billion but missed the consensus estimate of $2.52 billion.The company’s diversified fresh produce portfolio helped offset pressure in Fresh Fruit, where higher sourcing, fuel and shipping costs weighed on profitability. Diversified Fresh Produce - Americas & ROW delivered strong growth, with revenues rising 13.9% to $440.1 million and adjusted EBITDA increasing 33.8% to $20.6 million.Dole’s shares have lost roughly 6% during yesterday's trading session, due to soft quarterly results. This Zacks Rank #3 (Hold) company’s shares have fallen 9.4% in the past three months, wider than the industry’s 6.4% decline. Image Source: Zacks Investment Research Dole’s second-quarter revenue growth reflected positive operational performance and favorable foreign currency translation. On a like-for-like basis, revenues increased 1.7%, or $40.7 million, as the company continued to see resilient consumer demand for fresh produce.Gross profit declined 10.5% year over year to $195.3 million as cost of sales increased at a faster rate than revenues. Operating income decreased 54% to $47.5 million from $103.2 million, pressured by lower gross profit, higher selling, marketing, general and administrative expenses, a non-recurring legal settlement charge and lower gains from asset sales compared with the prior-year period. Fresh Fruit revenues were $972.8 million, broadly unchanged from the prior year. Higher banana volumes in Europe and stronger underlying banana pricing in North America were offset by lower banana volumes in North America and weaker pineapple volumes due to adverse weather conditions.Fresh Fruit adjusted EBITDA declined 30.9% to $50.3 million, primarily due to higher fruit sourcing costs, elevated shipping costs, increased pineapple growing costs and the continued appreciation of the Costa Rican Colon against the U.S. dollar. Dole PLC price-consensus-eps-surprise-chart | Dole PLC Quote Diversified Fresh Produce - EMEA generated revenues of $1.1 billion, up 1% year over year, driven by favorable foreign currency movements and underlying growth in Scandinavia. This was partially offset by lower revenues in Spain. Adjusted EBITDA decreased 6.2% to $45.9 million as weaker results in South Africa, the Netherlands and Spain outweighed strength in Scandinavia.Diversified Fresh Produce - Americas & ROW remained a key contributor to results. Revenues increased 13.9% year over year, supported by higher volumes in North America, particularly kiwi, avocados and cherries, along with positive season-end pricing adjustments in the Southern Hemisphere export business. Adjusted EBITDA increased 33.8% year over year to $20.6 million. Dole continued to advance its capital allocation plans during the quarter. The company completed the Ecuador port sale after quarter-end, generating expected net proceeds of about $95 million. The transaction is expected to strengthen financial flexibility.Net debt was $746.1 million at the end of the quarter, while net leverage stood at 2.0x. Capital expenditures totaled approximately $42.5 million during the six months of 2026, with investments focused on future growth, capacity expansion and operating efficiency. For 2026, Dole continues to expect routine capital expenditures of approximately $100 million.The company also repurchased 719,290 shares during the quarter for $10 million at an average price of $13.88 per share. As of June 30, 2026, $85.4 million was available for repurchase under its repurchase program.On Aug. 7, 2026, the company’s board declared a cash dividend for the second quarter of 2026 of $0.085 per share, payable Oct 7, 2026, to shareholders of record as of Sept. 16, 2026. Dole projected its 2026 adjusted EBITDA of approximately $400 million. Management expects the operating environment to remain complex due to elevated fuel and shipping costs, and ongoing geopolitical uncertainty.The company expects benefits from fuel surcharge recoveries, cost-saving initiatives in Fresh Fruit, dynamic pricing across diversified businesses and returns from recent investments. Management also highlighted plans to invest in automation, Artificial Intelligence and warehouse solutions in Scandinavia following the acquisition of Greenfood’s Fresh Produce division. Darling Ingredients Inc. DAR, which is a global developer and producer of sustainable natural ingredients, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Darling Ingredients' current financial-year sales indicates growth of 12.4% from the prior-year level. DAR delivered a trailing four-quarter earnings surprise of 38.9%, on average.United Natural Foods UNFI, which is the leading distributor of natural, organic and specialty food and non-food products, currently carries a Zacks Rank #2 (Buy). The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.Medifast, Inc. MED, which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank of 2. MED missed the average earnings surprise by a sharp margin in the trailing four quarters. The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 25.9% from the year-ago number. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Dole PLC (DOLE) : Free Stock Analysis Report Darling Ingredients Inc. (DAR) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report MEDIFAST INC (MED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Primo Brands Corporation PRMB reported second-quarter 2026 adjusted earnings of 37 cents per share, up 2.8% compared with a year ago and surpassed the Zacks Consensus Estimate of 32 cents.Net sales rose 3.8% year over year to $1.80 billion and topped the consensus estimate of $1.76 billion. Management said top-line results exceeded expectations. Robust Retail channel growth led by regional spring water and premium brands, along with an earlier-than-expected return to growth in Direct Delivery, supported growth. This was partly offset by lower sales from the exited U.S. Office Coffee Services business.Following the earnings release, Primo Brands’ shares jumped more than 8% during the trading session. Shares of this Zacks Rank #2 (Buy) stock have risen 19.3% in the past six months, outperforming the industry’s 2.4% growth. Image Source: Zacks Investment Research Gross profit increased 1.4% year over year to $548.7 million, but the gross margin contracted 80 basis points to 30.5%. Higher transportation costs and depreciation and amortization weighed on profitability, while revenue growth and lower non-recurring integration costs provided a partial offset.Selling, general and administrative expenses dipped 8.7% year over year to $345.5 million. Lower marketing costs and reduced amortization tied mainly to definite-lived intangible assets helped operating income climb 59.8% year over year to $180.3 million.Adjusted EBITDA increased 5% to $385 million, with the margin rising 20 basis points year over year to 21.4%. Primo Brands Corporation price-consensus-eps-surprise-chart | Primo Brands Corporation Quote Regional spring water sales rose 4.1% year over year to $911 million, making it the largest water category. Purified water sales increased 1.9% to $556.1 million, while premium water advanced 30.5% to $114.2 million.Other water sales fell 9.7% to $31.8 million, and the broader Other category slipped 1.9% to $183.1 million. The category mix shows that regional spring and premium offerings were the primary engines of quarterly revenue growth. As of June 30, 2026, the company generated net cash from continuing operations of $331.7 million, up from $193.8 million seen a year ago. After $190 million in capital expenditures and $32.7 million of additions to intangible assets, free cash flow reached $109 million, up from $52.7 million registered a year ago. Adjusted free cash flow was $328.7 million as of June 30.As of June 30, 2026, total debt excluding unamortized debt costs and discounts was $5.3 billion. Unrestricted cash and cash equivalents totaled $366.5 million, resulting in net debt of $4.9 billion.During the quarter, PRMB paid $43.5 million in cash dividends and spent $15.5 million on share repurchases, including brokerage commissions. Primo Brands raised its 2026 net sales growth forecast to 2-4% from the prior range of 1-3%. The company reaffirmed adjusted EBITDA guidance of $1.465-$1.515 billion.Management also maintained base capital expenditures at 4% of net sales and adjusted free cash flow guidance of $790-$810 million. Darling Ingredients Inc. DAR, which is a global developer and producer of sustainable natural ingredients, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Darling Ingredients' current financial-year sales indicates growth of 12.4% from the prior-year level. DAR delivered a trailing four-quarter earnings surprise of 38.9%, on average.United Natural Foods UNFI, which is the leading distributor of natural, organic and specialty food and non-food products, currently carries a Zacks Rank of 2. The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.Medifast, Inc. MED, which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank of 2. MED missed the average earnings surprise by a sharp margin in the trailing four quarters. The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 25.9% from the year-ago number. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Primo Brands Corporation (PRMB) : Free Stock Analysis Report Darling Ingredients Inc. (DAR) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report MEDIFAST INC (MED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. Revenue has stabilized sequentially over recent quarters, driven by a third consecutive quarter of year-over-year coach productivity growth. The company is transitioning from the OPTAVIA brand to Trilivy, shifting the strategic focus from simple weight loss to a comprehensive metabolic health system. Management attributes the decline in active earning coaches to the rapid adoption of GLP-1 medications across the traditional weight loss category. The new '3.0 strategy' is defined by a 10-year roadmap focusing on speed, simplicity, scale, and stewardship to capture the metabolic health market. Coach productivity reached its highest level since Q2 2022, which management views as a leading indicator for future revenue and profitability growth. The launch of the Medifast Metabolic Health Institute aims to establish scientific authority and provide evidence-based education to differentiate the brand. Management targets a return to profitability by the fourth quarter of 2026 through a combination of revenue growth and cost elimination. The Catalyst program is expected to drive significant cost savings in Q3 and Q4 2026 through facility rationalization and AI-related efficiencies. Full-year 2026 revenue is projected between $270 million and $300 million, assuming continued stabilization of the top line. The company expects active earning coach counts to continue declining in the short term, though productivity per coach is expected to rise. Future growth is predicated on the 'flywheel' effect where increased coach productivity eventually leads to new coach acquisition and revenue scale. The company recorded a full valuation allowance against its deferred tax assets as of December 31, 2025, impacting the effective tax rate. A new enhanced compensation plan was launched on August 1st to incentivize the development of high-producing Executive Directors. MetaVantage Technology is being introduced in new 'Reset Fuelings' to target fat metabolism and insulin function as a key product differentiator. The Catalyst program execution in Q3 will involve one-time costs that are excluded from the current Q3 EPS guidance range. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here. Management confirmed the program aims for 'millions of dollars' in savings but declined to provide a specific figure until the Q3 earnings call. The focus is on simplifying the business without removing costs that would negatively impact top-line revenue generation. Profitability will be driven by top-line stabilization near the $70 million to $75 million quarterly range combined with Catalyst program savings. Management expects improved margins as the business stops losing leverage on fixed costs through revenue stabilization. Initial feedback from the coach convention and product pre-launch has been positive, with no major hiccups reported in the brand evolution. The transition allows coaches to move beyond weight loss narratives into a broader metabolic health platform, which management believes expands the total addressable market.

Interested in Medifast Inc? Here are five stocks we like better. Q2 performance weakened: Revenue fell 27.6% year over year to $76.4 million, and Medifast posted a $3.1 million net loss as its active earning coach base declined nearly 49%. However, revenue per active coach increased 41% to $6,529, marking a third consecutive quarter of productivity improvement. Trilivy anchors the strategic reset: Medifast is shifting from traditional weight loss toward metabolic health through its new Trilivy brand, upcoming Reset Fuelings, the Metabolic Health Institute and an enhanced coach compensation plan. Management is targeting a Q4 return to profitability: The Catalyst cost program is expected to generate millions in savings through facility rationalization, AI efficiencies and other streamlining. Medifast ended June with $169.8 million in cash and investments, no debt, and reiterated its fourth-quarter 2026 profitability goal. LifeMD Can Surge on Its GLP-1 Offerings Medifast (NYSE:MED) reported second-quarter 2026 revenue of $76.4 million, down 27.6% from a year earlier, as its active earning coach base continued to decline amid the rapid adoption of GLP-1 medications across the traditional weight-loss category. The company posted a net loss of $3.1 million, or $0.28 per diluted share, compared with net income of $2.5 million, or $0.22 per share, in the prior-year quarter. Management said revenue met its guidance range and earnings per share exceeded guidance, supported by a third consecutive quarter of improvement in coach productivity. Medifast ended the quarter with about 11,700 active earning coaches, a 48.7% decrease from the second quarter of 2025. However, average revenue per active earning coach rose 41% year over year to $6,529 and increased 20% sequentially, reaching its highest level since the second quarter of 2022. → Lost in Space: Why Aerospace Valuations Are Plummeting Right Now LifeMD Shares Come Back to Life on GLP-1 Business Growth “We now have a clear trend of increasing coach productivity both year-over-year and sequentially,” Chief Financial Officer Jim Maloney said. The company views higher revenue per coach as an early indicator that could eventually lead to coach growth and revenue growth. Chief Executive Officer Nicholas Johnson, speaking on his first earnings call in the role, said the company is pursuing a broader transition from weight loss toward metabolic health. Medifast launched its Trilivy consumer brand as the successor to OPTAVIA and described it as the first step in its “3.0 strategy,” a 10-year roadmap focused on expanding its offerings, geographic reach and demographic footprint. → MarketBeat Week in Review – 07/27- 07/31 Are These Consumer Staples Too Cheap for Investors To Ignore? Johnson said Trilivy is designed around three phases—reset, refine and renew—and positions the company’s coach-led nutrition programs as a comprehensive metabolic health system. The company also launched the Medifast Metabolic Health Institute in July, which will organize research, product development, scientific communications and education. The company plans to introduce new Reset Fuelings later in August. The products include Medifast’s MetaVantage Technology Reset Formula, which the company said is intended to support normal fat metabolism, healthy insulin function and reduced waist circumference. Johnson said a spring pilot involving certain employees, coaches and clients generated “overwhelmingly positive” feedback. → GE HealthCare Stock Climbs on Vital Diagnostics Demand Medifast also launched an enhanced coach compensation plan on Aug. 1, emphasizing the development of executive directors. Johnson said executive directors are the company’s highest-producing coaches and represent “the single greatest driver of sustainable growth” for the business. The percentage of active earning coaches at the executive director rank or above remained above the company’s 10% benchmark for a healthy and scalable field organization, he said. Gross profit declined 30.3% year over year to $53.4 million, while gross margin fell to 69.9% from 72.6%. Maloney attributed the margin decline primarily to a loss of leverage on fixed costs as sales volumes decreased. Selling, general and administrative expense fell 25.7% to $57.7 million. The reduction included a $12.6 million decline in coach compensation, a $2.3 million reduction in employee salary and benefits expense, and a $2 million decrease in company-led marketing costs. Still, SG&A as a percentage of revenue increased by 200 basis points because of lower fixed-cost leverage and costs related to the Trilivy Reset product launch. Medifast recorded an operating loss of $4.3 million, compared with an operating loss of approximately $1 million in the second quarter of 2025. Other income declined to $1.3 million from the prior-year period, primarily because the earlier quarter included gains on LifeMD common stock that Medifast sold during the second quarter of 2025. Medifast launched its Catalyst program during the second quarter, with most execution expected in the third quarter. The initiative is intended to generate cost savings through facility rationalization, AI-related efficiencies and other streamlining measures. Maloney said the company expects “millions of dollars of savings” but has not yet quantified the program because management is still determining which costs to reduce. He said Medifast expects to provide more detail during its third-quarter earnings call and stressed that the company does not intend to make cuts that would impair revenue growth. Management reiterated its objective of returning to profitability in the fourth quarter of 2026, citing top-line stabilization, the new product rollout and cost reductions under Catalyst. Maloney said the company expects improved margins as revenue stabilizes and as the business gains operating leverage over time. Third-quarter revenue guidance: $60 million to $80 million. Third-quarter loss-per-share guidance: $0.15 to $0.65, excluding one-time Catalyst execution costs. Full-year 2026 revenue guidance: $270 million to $300 million. Full-year 2026 loss-per-share guidance: $0.25 to $1.75. Expected working capital at Dec. 31, 2026: More than $145 million. Medifast held $169.8 million in cash equivalents and investments and had no debt as of June 30. Johnson said the company’s balance sheet provides financial flexibility as it rolls out Trilivy and works toward its fourth-quarter profitability target. Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client's weight‐loss journey. Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "Medifast Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

This article first appeared on GuruFocus. Revenue: $76.4 million in Q2 2026, a decrease of 27.6% year over year, in line with guidance. Gross Profit: $53.4 million, down 30.3% year over year, with gross margin at 69.9% compared to 72.6% in Q2 2025. SG&A Expense: $57.7 million, down 25.7% year over year, driven by lower coach compensation and reduced marketing costs. Operating Loss: $4.3 million, an increase in losses of $3.3 million versus the prior year period. Net Loss: $3.1 million, or $0.28 per diluted share, compared to net income of $2.5 million, or $0.22 per share, in Q2 2025. Active Earning Coaches: Approximately 11,700, a decrease of 48.7% from Q2 2025. Revenue per Active Earning Coach: $6,529, a year-over-year increase of 41.0%. Cash and Investments: $169.8 million with no debt as of June 30, 2026. Q3 2026 Guidance: Revenue expected between $60 million and $80 million; loss per share between $0.15 and $0.65. Full Year 2026 Guidance: Revenue expected between $270 million and $300 million; loss per share between $0.25 and $1.75. Warning! GuruFocus has detected 2 Warning Signs with MED. Is MED fairly valued? Test your thesis with our free DCF calculator. Release Date: August 03, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Revenue has stabilized sequentially over recent quarters, with coach productivity growing for the third consecutive quarter. Active earning coach productivity increased 41% year-over-year and 20% sequentially, reaching the highest level since Q2 2022. The launch of the new Trilivy brand and MetaVantage technology platform strengthens market differentiation in the metabolic health category. The company maintains a strong balance sheet with over $169 million in cash and investments and no debt. The new enhanced compensation plan and coach training platform are designed to improve field performance and drive sustainable growth. Revenue decreased 27.6% year-over-year to $76.4 million, driven by a 48.7% decline in active earning coaches. The company continues to face headwinds from the rapid adoption of GLP-1 medications, impacting the traditional weight loss category. Gross profit margin declined to 69.9% from 72.6% due to loss of leverage on fixed costs. Net loss of $3.1 million in Q2 2026, compared to net income of $2.5 million in the prior year period. The company expects active earning coach count to continue declining in the short-term, with Q3 revenue guidance of $60-80 million indicating potential further weakness. Q: Can you provide more detail on the initial implementation costs of the Catalyst program, the expected savings, and the cadence of when we should see the cost flow through the P&L versus the realization of the savings? A: (James Maloney, CFO) We are being intentional in saying there is more to come on the Catalyst program and its savings. We believe there are millions of dollars in savings, but we are not able to quantify it yet because we are working through what we plan to reduce. The focus is to simplify the business without taking out costs that will impact top-line revenues. We will provide exact quantifications on our Q3 earnings call. Q: Is the Catalyst program the only lever to return to profitability in Q4, or are there other incremental contributors like top-line recovery or the new product launch? A: (James Maloney, CFO) We kept our top-line guidance the same versus last quarter. We are targeting the revenue range of $60 million to $80 million for Q3, and we are feeling more confident in that top-line. The EPS range we provided has actually improved. Even though we are excluding certain one-time charges, when you do the math for Q4, you will see how the profitability picture gets better. Q: Can you walk us through the coach receptivity to the new Trilivy product offering, the transition from the old OPTAVIA system, and any incremental opportunities the new platform provides? A: (Nicholas Johnson, CEO) We saw a tremendous amount of positive reception to the change, notably around our ability to develop a metabolic health platform that goes beyond weight loss. The coach pre-launch of the new Trilivy Fuelings has been very positive, and we have seen no major hiccups. We have a plan to roll out those Fuelings across the next quarters. (James Maloney, CFO) Stabilization of our top-line will help our margins, and the impact of Catalyst should also help. As the business stabilizes and grows, the loss of leverage from fixed costs becomes a positive. Q: What is the current state of coach productivity and how does it relate to future revenue growth? A: (Nicholas Johnson, CEO) Active earning coach productivity was positive for the third straight quarter, with year-over-year productivity up 41% and sequentially up 20% versus Q1. Revenue per active earning coach is now the highest it has been since Q2 2022. We believe increases in revenue per active earning coach are an early indicator for future coach growth, which will lead to revenue growth. Q: What is the significance of the new Trilivy brand and the Medifast Metabolic Health Institute for the company's long-term strategy? A: (Nicholas Johnson, CEO) Trilivy is the first step in our 3.0 strategy, the biggest shift since we launched OPTAVIA in 2017. It reflects the holistic health benefits our system delivers through three phases: Reset, Refine, and Renew. The Medifast Metabolic Health Institute, launched in July, is designed to strengthen the evidence base behind our programs and establish Medifast as a trusted authority in metabolic health, turning our scientific heritage into a durable competitive advantage. Q: How is the company addressing the impact of GLP-1 medication adoption on its business? A: (Nicholas Johnson, CEO) We continue to engage the GLP-1 market and beyond, supporting people throughout their health journey, whether they are using medication, coming off it, or pursuing metabolic health through non-medication pathways. Our coach-led program builds on more than 45 years of clinical heritage and is built around metabolic synchronization, our proprietary science that reverses metabolic dysfunction. Q: What are the key financial results for the second quarter of 2026? A: (James Maloney, CFO) Revenue was $76.4 million, a decrease of 27.6% year-over-year, primarily due to a decrease in active earning coaches. Gross profit margin was 69.9% compared to 72.6% in the prior year. Net loss was $3.1 million or $0.28 per diluted share, compared to net income of $2.5 million in the year-ago period. We ended the quarter with $169.8 million in cash and investments and no debt. Q: What is the company's guidance for the third quarter and full year 2026? A: (James Maloney, CFO) For Q3, we expect revenue to range from $60 million to $80 million and loss per share to range from $0.15 to $0.65, excluding one-time Catalyst costs. For the full year, we expect revenue to range from $270 million to $300 million and loss per share between $0.25 and $1.75. We continue to expect improvements to get back to profitability starting in Q4 2026. Q: How is the new enhanced compensation plan expected to impact the field organization? A: (Nicholas Johnson, CEO) On August 1, we launched an enhanced compensation plan that sharpens our focus on developing and duplicating executive directors, who are the single greatest driver of sustainable growth. The design was informed by our EDGE program, which confirmed that focusing on building executive directors empowers stronger leadership development. The percentage of active earning coaches at the executive director rank or above continues to climb, remaining over our 10% benchmark for a healthy, scalable field organization. Q: What is the company's near-term focus and how does it plan to achieve profitability? A: (Nicholas Johnson, CEO) Our near-term focus is straightforward: we aim to return to profitability by Q4 2026. We are executing on both sides of the equation, enhancing initiatives to grow revenue and eliminating costs across the business through the Catalyst program. We are running the organization on the key tenets of speed, simplicity, scale, and stewardship, and we believe we are on track to deliver on our objectives. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Archer Daniels Midland Company ADM posted second-quarter 2026 adjusted earnings of $1.84 per share, up 98% year over year. The figure surpassed the Zacks Consensus Estimate of $1.42 by 29.6%. On a reported basis, earnings were $1.87 per share, substantially up from 45 cents in the year-ago quarter.Revenues increased 7.1% to $22.68 billion and beat the consensus estimate of $22.38 billion. Results benefited from margin expansion in Ag Services and North American crushing and robust ethanol economics.  Global oilseed volumes increased roughly 5% compared with the prior-year quarter.Total segment operating profit increased 75% year over year to $1.5 billion, reflecting broad-based growth across all three operating segments.We note that shares of this Zacks Rank #2 (Buy) company have gained 22.8% in the past six months compared with the industry’s 6.6% growth. Image Source: Zacks Investment Research Ag Services and Oilseeds revenues increased 10.1% year over year to $17.9 billion. Carbohydrate Solutions revenues declined 1.3% to $2.8 billion, while Nutrition revenues fell 4.6% to $1.9 billion. Other Business revenues decreased 5.4% to $106 million. The Zacks Consensus Estimate for revenues is pegged at $17.5 billion for Ag Services and Oilseeds, $2.9 billion for Carbohydrate Solutions and $2 billion for Nutrition.The company processed 9.5 million metric tons of oilseeds, up 4.7% from the prior-year quarter and surpassed the Zacks Consensus Estimate of 9.3 million metric tons. Corn processing volumes rose 2.6% to 4.7 million metric tons. Higher asset utilization supported the improvement in global oilseed volumes. Archer Daniels Midland Company price-consensus-eps-surprise-chart | Archer Daniels Midland Company Quote Ag Services and Oilseeds operating profit surged 129% to $867 million. Results included roughly $100 million of net positive mark-to-market and timing impacts, mainly within Crushing. Margin expansion in Ag Services and North American crushing provided the primary lift.Ag Services operating profit climbed 159% to $293 million as ADM leveraged its global asset network and benefited from increased soybean exports and the return of its Barcarena, Brazil, terminal to full operations. Crushing profit substantially jumped to $363 million from $33 million, supported by stronger biofuel margins, elevated energy prices and record meal exports from Brazil and the United States. Carbohydrate Solutions operating profit increased 22% year over year to $411 million. Robust North American ethanol margins, policy incentives, elevated energy prices and lower U.S. corn prices improved ethanol’s economics relative to competing blendstocks. These conditions supported higher domestic blend rates and favorable industry exports.Starches and Sweeteners operating profit rose 7% year over year to $326 million as stronger wet-milling ethanol margins offset lower liquid sweetener volumes and margins. Vantage Corn Processors’ profit increased 158% year over year to $85 million, aided by strengthening dry-milling ethanol margins and effective risk management. Nutrition operating profit advanced 51% year over year to $172 million, with improvement across Human Nutrition and Animal Nutrition. Human Nutrition operating profit increased 51% to $139 million, driven by Flavors growth, seasonal momentum and continued progress at the Decatur East plant.Animal Nutrition operating profit grew 50% to $33 million. The increase reflected operational improvements and benefits from portfolio actions completed during 2025. The segment’s performance extended ADM’s recovery beyond its commodity-processing businesses. The company ended the quarter with cash and cash equivalents of $1.1 billion, long-term debt, including current maturities, of $7.6 billion, and shareholders’ equity of $23.6 billion. As of June 30, 2026, ADM generated $1.3 billion in cash from operating activities. It paid dividends of $510 million in the reported quarter. ADM raised its 2026 adjusted earnings guidance to approximately $5.15-$5.60 per share from the previous range of $4.15-$4.70. The revised outlook assumes year-over-year improvement in crushing and ethanol, supported by disciplined execution and a constructive margin environment.Management tied the stronger outlook primarily to finalized renewable volume obligations under the U.S. Renewable Fuel Standard, global trade dynamics and higher energy prices. The company continues to project 2026 capital expenditures of $1.3-$1.5 billion while monitoring macroeconomic, geopolitical, policy and trade conditions. Darling Ingredients Inc. DAR, which is a global developer and producer of sustainable natural ingredients, currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The Zacks Consensus Estimate for Darling Ingredients' current financial-year sales indicates growth of 12.4% from the prior-year level. DAR delivered a trailing four-quarter earnings surprise of 38.9%, on average. United Natural Foods UNFI, which is the leading distributor of natural, organic and specialty food and non-food products, currently carries a Zacks Rank of 2. The Zacks Consensus Estimate for United Natural Foods’ current financial-year sales indicates a drop of 2.1% from the prior-year level. UNFI delivered a trailing four-quarter earnings surprise of 29.9%, on average.Medifast, Inc. MED, which is a leading manufacturer and distributor of clinically-proven healthy living products and programs, currently carries a Zacks Rank of 2. MED missed the average earnings surprise by a sharp margin in the trailing four quarters. The Zacks Consensus Estimate for Medifast’s current financial-year sales indicates a decline of 25.9% from the year-ago number. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Archer Daniels Midland Company (ADM) : Free Stock Analysis Report Darling Ingredients Inc. (DAR) : Free Stock Analysis Report United Natural Foods, Inc. (UNFI) : Free Stock Analysis Report MEDIFAST INC (MED) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research